Literature DB >> 18497026

Relevance of the concept of oncogene addiction to hormonal carcinogenesis and molecular targeting in cancer prevention and therapy.

Bernard Weinstein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18497026     DOI： 10.1007/978-0-387-69080-3_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  10 in total

Review 1.  Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight.

Authors:  Suzanne A W Fuqua; Guowei Gu; Yassine Rechoum
Journal:  Breast Cancer Res Treat       Date:  2014-02-01       Impact factor: 4.872

2.  A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels.

Authors:  Christine M Stellrecht; Mary Ayres; Rishi Arya; Varsha Gandhi
Journal:  Breast Cancer Res Treat       Date:  2009-07-30       Impact factor: 4.872

Review 3.  Targeting CDK4 and CDK6: From Discovery to Therapy.

Authors:  Charles J Sherr; David Beach; Geoffrey I Shapiro
Journal:  Cancer Discov       Date:  2015-12-11       Impact factor: 39.397

4.  Is the bench getting closer to the bedside in the war on cancer? A quick look at prostate cancer.

Authors:  Robert Kypta; Miguel Unda; Arkaitz Carracedo
Journal:  Front Endocrinol (Lausanne)       Date:  2012-04-12       Impact factor: 5.555

5.  EPMA position paper in cancer: current overview and future perspectives.

Authors:  Godfrey Grech; Xianquan Zhan; Byong Chul Yoo; Rostyslav Bubnov; Suzanne Hagan; Romano Danesi; Giorgio Vittadini; Dominic M Desiderio
Journal:  EPMA J       Date:  2015-04-15       Impact factor: 6.543

Review 6.  For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors.

Authors:  Christina M Buchanan; Kate L Lee; Peter R Shepherd
Journal:  Biomolecules       Date:  2019-08-22

7.  MIP-2A is a novel target of an anilinoquinazoline derivative for inhibition of tumour cell proliferation.

Authors:  Mayuko Tokunaga; Hirokazu Shiheido; Noriko Tabata; Yuko Sakuma-Yonemura; Hideaki Takashima; Kenichi Horisawa; Nobuhide Doi; Hiroshi Yanagawa
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

8.  Stratification and therapeutic potential of PML in metastatic breast cancer.

Authors:  Natalia Martín-Martín; Marco Piva; Jelena Urosevic; Paula Aldaz; James D Sutherland; Sonia Fernández-Ruiz; Leire Arreal; Verónica Torrano; Ana R Cortazar; Evarist Planet; Marc Guiu; Nina Radosevic-Robin; Stephane Garcia; Iratxe Macías; Fernando Salvador; Giacomo Domenici; Oscar M Rueda; Amaia Zabala-Letona; Amaia Arruabarrena-Aristorena; Patricia Zúñiga-García; Alfredo Caro-Maldonado; Lorea Valcárcel-Jiménez; Pilar Sánchez-Mosquera; Marta Varela-Rey; Maria Luz Martínez-Chantar; Juan Anguita; Yasir H Ibrahim; Maurizio Scaltriti; Charles H Lawrie; Ana M Aransay; Juan L Iovanna; Jose Baselga; Carlos Caldas; Rosa Barrio; Violeta Serra; Maria dM Vivanco; Ander Matheu; Roger R Gomis; Arkaitz Carracedo
Journal:  Nat Commun       Date:  2016-08-24       Impact factor: 14.919

Review 9.  Oncogenes in immune cells as potential therapeutic targets.

Authors:  Gulnur K Zakiryanova; Sarah Wheeler; Michael R Shurin
Journal:  Immunotargets Ther       Date:  2018-04-11

10.  Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets.

Authors:  Olga Y Korolkova; Sarrah E Widatalla; Diva S Whalen; Gladys N Nangami; Adeniyi Abimbola; Stephen D Williams; Heather K Beasley; Emily Reisenbichler; Mary Kay Washington; Josiah Ochieng; Ingrid A Mayer; Brian D Lehmann; Amos M Sakwe
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.